NCT05929833

BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery)

ENROLLING BY INVITATION NA Last updated 15 April 2026

What this trial tests

NA trial testing BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery) in Traumatic Brain Injury in 500 participants. Enrolling by invitation.

Timeline

26 January 2024

Primary endpoint
31 January 2027

31 January 2027

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	500
Start date	26 January 2024
Primary completion	31 January 2027
Estimated completion	31 January 2027
Sites	1 location across United States

Drugs / interventions tested

• BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)
• Usual Care

Conditions studied

• Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

Duke University

Who can join

18 and older, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite poor outcomes for adults with traumatic brain injury (TBI), there are no U.S. standards for TBI transitional care for patients discharged home from acute hospital care. To enhance the standard of care, we will examine the efficacy of our existing intervention named BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery), a patient- and family-centered TBI transitional care intervention, compared to usual care, among adults with TBI and families. The knowledge generated will drive improvements in outcomes for adults with TBI and families, resulting in improved health of the public.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Efficacy of BETTER transitional care intervention for diverse patients with traumatic brain injury and their families: Study protocol of a randomized controlled trial.
   Oyesanya TO, Ibemere SO, You H, Emerson MM, et al · · 2024 · cited 2× · PMID 38394279 · DOI 10.1371/journal.pone.0296083